I'm LongbridgeAI, I can summarize articles.Legend Biotech (LEGN) rose 4.27% this week to close at $19.27, while the S&P 500 slipped 0.47%, putting the stock roughly 4.74 percentage points ahead of the broader market. The week was choppy: Monday (19 Oct) opened lower, dipped to $17.995, then recovered to $18.65. Tuesday touched a high of $19.15, Wednesday pulled back to $18.63, Thursday drifted sideways, and Friday pushed back up to close near the week’s high at $19.27.
The Week
Legend Biotech (LEGN) rose 4.27% this week to close at $19.27, while the S&P 500 slipped 0.47%, putting the stock roughly 4.74 percentage points ahead of the broader market. The week was choppy: Monday (19 Oct) opened lower, dipped to $17.995, then recovered to $18.65. Tuesday touched a high of $19.15, Wednesday pulled back to $18.63, Thursday drifted sideways, and Friday pushed back up to close near the week’s high at $19.27. There was no major catalyst this week, with weekly amplitude around 6.98% and relatively thin turnover.
Analyst Ratings
Among 13 brokers covering Legend Biotech, 8 rate it buy or overweight, while 5 rate it hold; none rate it underweight or sell. The consensus rating is buy, with a consensus target of $45.62231, about 136.75% above the current price of $19.27. The target range is wide, from $24.00 to $68.00, reflecting clear disagreement about the upside. Legend Biotech ranks 90th by analyst rating within the biotechnology industry, out of 511 companies.
The Week Ahead
Macro data is heavy next week: on Tuesday (27 Oct), the US reports durable goods orders, new home sales, consumer confidence, and FHFA and Case Shiller home price indices. Softer prints could weigh on high-multiple sectors like biotech. More importantly, Legend Biotech’s Q3 FY2026 earnings are scheduled for Thursday, 12 Nov, with estimates at $0.0118 EPS and $360m revenue, offering a key checkpoint after this quiet stretch.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.